Off-the-Shelf CAR t cells take on tough blood cancers
NCT ID NCT05995015
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new 'universal' CAR T cell therapy (4SCAR19U) for people with B cell cancers that have come back or not responded to treatment. The therapy uses donor-derived immune cells engineered to target CD19 on cancer cells. The study aims to check safety and see if the cells shrink tumors, enrolling 30 participants across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Universal CD19-specific CAR T cells (4SCAR19U)
What this could lead to
If it works, this could lead to a more accessible 'off-the-shelf' CAR T cell therapy for people with hard-to-treat B cell cancers.
What could go wrong
This is a very early phase 1 trial with only 30 people. The therapy may not work, could cause severe side effects like cytokine release syndrome, and long-term control is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shenzhen Geno-Immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••